GRAND PHARMA (00512): Six Products Successfully Included in the 2026 National Reimbursement Drug List, the Commercial Insurance Innovative Drug Catalog, and Industry Supporting Lists
GRAND PHARMA (00512) announced that recently, a total of six products of the Group were successfully included in the "National Basic Medical Insurance, Maternity Insurance, and Work-Related Injury Insurance Drug Catalog (2026)" and the "Commercial Health Insurance Innovative Drug Catalog (2026)" issued by the National Healthcare Security Administration of the People's Republic of China (NHSA), the "Recommended List of Drugs Covered by Commercial Health Insurance (First Edition)" issued by the Insurance Association of China, or the "Drugs Involved in the Calculation of Commercial Health Insurance Coverage Costs" issued by the China Association of Actuaries.
GRAND PHARMA (00512) announced that recently, a total of six of the Group's products were successfully included in the "National Basic Medical Insurance, Maternity Insurance and Work Injury Insurance Drug Catalog (2026)" and the "Commercial Health Insurance Innovative Drug Catalog (2026)" issued by the National Healthcare Security Administration of the People's Republic of China (NHSA), the "Recommended List of Commercial Health Insurance Drug Coverage (First Edition)" issued by the Insurance Association of China, or the "Drugs Involved in the Calculation of Commercial Health Insurance Coverage Costs" issued by the China Association of Actuaries.
The six products include: Yigantai (Yttrium-90 [90Y] Microsphere Injection), which was successfully selected for the first time into the commercial insurance innovative drug catalog and recommended list; Laiteling (Olopatadine and Mometasone Nasal Spray), which was included for the first time in the National Medical Insurance Drug Catalog; Enzhuorun Bishihai (Indacaterol, Glycopyrronium and Mometasone Inhalation Powder II) and Enmingrun Bishihai (Indacaterol and Mometasone Inhalation Powder II, III), as well as Limeitong (Eplerenone Tablets), which successfully renewed their contracts and remain in the National Medical Insurance Drug Catalog; and Anweide (Carglumic Acid Dispersible Tablets), which was included for the first time in the commercial insurance coverage cost table.
The Group believes that the coordinated linkage between medical insurance and commercial insurance is an important measure under the national policy of "ensuring basic coverage and promoting innovation" and strongly supporting the high-quality development of innovative drugs. Through diversified access pathways, the Group's six products have been connected to the multi-tiered medical security system, which will not only help improve medication accessibility for patients in the relevant disease areas and effectively reduce treatment burdens, but will also further accelerate market penetration and coverage of the products, forming a virtuous cycle from the payment side to the clinical side and laying a solid foundation for long-term high-quality growth.
Related Articles

GENFLEET-B(02595): Pan-RAS inhibitor GFH276 combination therapy study in pancreatic cancer completes first patient dosing in China and overseas; Phase II stage will include three first-line combination treatment regimens

Palm Eco-Town Development (002431.SZ) initiates out-of-court restructuring matters.

BEKE-W (02423) repurchased 422,900 shares for US$2.5 million on November 13.
GENFLEET-B(02595): Pan-RAS inhibitor GFH276 combination therapy study in pancreatic cancer completes first patient dosing in China and overseas; Phase II stage will include three first-line combination treatment regimens

Palm Eco-Town Development (002431.SZ) initiates out-of-court restructuring matters.

BEKE-W (02423) repurchased 422,900 shares for US$2.5 million on November 13.






